Market Overview

Geron, Angiochem Enter License Pact

Related GERN
One Way To Bet On The American Society Of Hematology's Meeting Next Month
Morning Market Gainers

The deal will provide Geron (NASDAQ: GERN) with a worldwide exclusive license to Angiochem's proprietary peptide technology that facilitates the transfer of anti-cancer compounds across the blood-brain barrier to be used with tubulin disassembly inhibitors, including the Company's product candidate GRN1005. As a result of the Company's determination to discontinue the development of GRN1005 as described elsewhere in this Current Report on Form 8-K, on December 3, 2012, Geron provided notice to Angiochem that Geron is terminating the License Agreement. Termination of the License Agreement will be effective on June 1, 2013.

Posted-In: News


Related Articles (GERN)

Get Benzinga's Newsletters